Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.
暂无分享,去创建一个
[1] S. Ganta,et al. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. , 2009, Molecular pharmaceutics.
[2] J. Ware,et al. Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice , 2009, Pharmaceutical Research.
[3] H. Devalapally,et al. Multi-functional nanocarriers for targeted delivery of drugs and genes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[4] S. Ganta,et al. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. , 2008, International journal of pharmaceutics.
[5] Z. Duan,et al. Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles , 2008, Clinical Cancer Research.
[6] Jen-kun Lin,et al. Curcumin: a Potential Cancer Chemopreventive Agent through Suppressing NF-κB Signaling , 2008 .
[7] S. Nie,et al. Therapeutic Nanoparticles for Drug Delivery in Cancer , 2008, Clinical Cancer Research.
[8] R. Samstein,et al. The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. , 2008, Biomaterials.
[9] Tushar K. Vyas,et al. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. , 2008, International journal of pharmaceutics.
[10] J. Tagne,et al. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. , 2008, Molecular pharmaceutics.
[11] Dong Yun Lee,et al. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[12] S. Goodin. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[13] S. Ambudkar,et al. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin , 2007, Molecular and Cellular Biochemistry.
[14] L. Lim,et al. Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats , 2007, Drug Metabolism and Disposition.
[15] S. B. Tiwari,et al. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. , 2006, Journal of nanoscience and nanotechnology.
[16] J. Beijnen,et al. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer , 2006, British Journal of Cancer.
[17] S. Ambudkar,et al. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1) , 2006, Cancer Chemotherapy and Pharmacology.
[18] Dipak K. Sarker. Engineering of nanoemulsions for drug delivery. , 2005, Current drug delivery.
[19] S. Ambudkar,et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. , 2004, Biochemical pharmacology.
[20] B. Aggarwal. Nuclear factor-κB: The enemy within , 2004 .
[21] K. Marumo,et al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. , 2004, Japanese journal of clinical oncology.
[22] S. Benita,et al. Enhanced Oral Absorption of Paclitaxel in a Novel Self-Microemulsifying Drug Delivery System with or Without Concomitant Use of P-Glycoprotein Inhibitors , 2004, Pharmaceutical Research.
[23] Samuel A Wickline,et al. Nanotechnology for molecular imaging and targeted therapy. , 2003, Circulation.
[24] Z. Duan,et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. , 2003, Current cancer drug targets.
[25] J. Schellens,et al. Oral Delivery of Taxanes , 2001, Investigational New Drugs.
[26] L. Denis,et al. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] G R Wilkinson,et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[28] Y. Lo,et al. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. , 2000, Biochemical pharmacology.
[29] D. Rose,et al. Omega-3 fatty acids as cancer chemopreventive agents. , 1999, Pharmacology & therapeutics.
[30] M. Seiden,et al. Progress in gynecologic oncology. , 1999, The oncologist.
[31] J. Beijnen,et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] N. Vermeulen,et al. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. , 1996, Biochemical pharmacology.
[33] H. Ohshima,et al. Physicochemical Characterization of Parenteral Lipid Emulsion: Influence of Cosurfactants on Flocculation and Coalescence , 1995, Pharmaceutical Research.
[34] K. Miyajima,et al. Phospholipid monolayers at the triolein-saline interface: production of microemulsion particles and conversion of monolayers to bilayers. , 1990, Biochemistry.
[35] B. Aggarwal,et al. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. , 2009, The international journal of biochemistry & cell biology.
[36] S. Ganta,et al. Microfluidic Preparation of Chlorambucil Nanoemulsion Formulations and Evaluation of Cytotoxicity and Pro-Apoptotic Activity in Tumor Cells , 2008 .
[37] R. Panchagnula,et al. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. , 2007, The Journal of investigative dermatology.
[38] Sung-Joo Hwang,et al. Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-Glycoprotein Inhibitor KR30031 , 2004, Pharmaceutical Research.
[39] B. Aggarwal,et al. Anticancer potential of curcumin: preclinical and clinical studies. , 2003, Anticancer research.
[40] A Garg,et al. Nuclear transcription factor-κB as a target for cancer drug development , 2002, Leukemia.
[41] B. Hirst,et al. Comparison of bile salt perturbation of duodenal and jejunal isolated brush-border membranes. , 1990, Digestion.
[42] H. W. Veen,et al. transporters : structure , substrate specificities and physiological roles A Brief Overview , 2022 .